Clinical Trials With a Polyvalent Breast Cancer Vaccine
Abstract
Preclinical studies with passively administered monoclonal antibodies or vaccine induced antibodies against glycolipid and mucin antigens have protected mice from tumor recurrence, even when treatment was initiated after tumor challenge. This timing is comparable to the adjuvant setting in the clinic. The glycolipid LeY and mucin MUC1 are expressed at the cell surface of most breast cancer cells in over 80% of breast cancer biopsy specimens. The optimal approach for antibody induction against these antigens has been conjugation to the immunogenic carrier molecule KLH and mixture with the potent immunological adjuvant QS21. The LeY-KLH and MUC1-KLH plus QS-21 vaccines prepared and tested over the last year have resulted in high titer antibodies against the synthetic antigens which were of relatively modest titer against tumor cells expressing these antigens. While these vaccines could be included in future polyvalent vaccines, it is our impression that we can augment the relevant immunogenicity by the modifications proposed which should make the immunogens more closely resemble the natural antigens. Consequently, glycosylated MUC1 peptides and LeY clusters will be conjugated to KLH, mixed with QS21, and tested over the next year.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1999
- Accession Number
- ADB258807
Entities
People
- Philip Livingston
Organizations
- Memorial Sloan Kettering Cancer Center